PT-141

Most drugs for sexual dysfunction target blood flow. PT-141 targets the brain. Bremelanotide (PT-141) is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone that activates melanocortin receptors — primarily MC3R and MC4R — in central nervous system circuits governing sexual motivation and arousal [1] PMID: 17584134 .

The compound emerged from an unexpected discovery. In the late 1990s, researcher Mac Hadley self-experimented with melanotan II, a synthetic tanning peptide, and experienced an 8-hour erection. That observation redirected the research trajectory toward sexual dysfunction, and bremelanotide — MT-II's active metabolite with a distinct receptor profile — became the clinical candidate [2] PMID: 12851303 .

In June 2019, the FDA approved bremelanotide (brand name Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first melanocortin-based therapy to reach market. The approval was based on two pivotal Phase 3 trials (RECONNECT) demonstrating statistically significant improvements in sexual desire and reductions in associated distress [3] PMID: 33455598 .

II. What is this compound?

PT-141 (bremelanotide) is a cyclic heptapeptide lactam with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH and a molecular weight of 1025.2 daltons (C50H68N14O10). The cyclic structure — formed by a lactam bridge between aspartic acid and lysine residues — confers conformational stability and receptor selectivity that distinguish it from its parent compound melanotan II.

The peptide is a synthetic analog of α-melanocyte-stimulating hormone (α-MSH), one of several melanocortin peptides derived from the proopiomelanocortin (POMC) precursor. Unlike α-MSH, bremelanotide does not bind the MC2R (ACTH receptor) and instead exhibits selective nanomolar affinity for MC3R (Ki ≈ 4.1 nM) and MC4R (Ki ≈ 2.7 nM) [4] PMID: 17584134 .

What makes PT-141 mechanistically distinct from PDE5 inhibitors (sildenafil, tadalafil) is its site of action. PDE5 inhibitors work peripherally — they enhance nitric oxide–mediated vasodilation in genital tissue. PT-141 works centrally — it activates melanocortin receptors in the hypothalamus and limbic system, regions that process sexual motivation, desire, and arousal [5] PMID: 12851303 . This means PT-141 addresses the neurobiological component of sexual dysfunction rather than the vascular component.

The compound is administered subcutaneously (FDA-approved formulation) with approximately 100% bioavailability, a Tmax of 0.5–1.0 hours, and a half-life of 2.5–2.7 hours. Protein binding is low (21%), and elimination occurs primarily through renal excretion (64.8%) with a fecal component (22.8%). Metabolism involves hydrolysis of peptide bonds — standard for small peptides [6] PMID: 14963471 .

III. How it works

The core mechanism of PT-141 is melanocortin receptor activation in the central nervous system — not peripheral vasodilation. This is the critical distinction from every other approved sexual dysfunction drug.

When bremelanotide crosses the blood-brain barrier and binds MC4R in the paraventricular nucleus (PVN) of the hypothalamus, it triggers a cascade that includes ** oxytocin Oxytocin cyclic nonapeptide neuropeptide Neuropeptide studied for social bonding, wound healing & pain modulation neuron activation** and downstream signaling through spinal oxytocinergic pathways [7] PMID: 17584134 . In male animal models, this produces penile erection through a mechanism independent of the nitric oxide–cGMP pathway targeted by PDE5 inhibitors. In female models, it evokes pre-copulatory behaviors analogous to sexual arousal [8] PMID: 12851303 .

MC3R agonism adds a reward-dimension. Bremelanotide's binding to MC3R receptors in the mesolimbic dopamine system — including the nucleus accumbens, medial preoptic area, and ventral tegmental area — is thought to modulate the hedonic and motivational aspects of sexual response [9] PMID: 33455598 . This dual-receptor engagement (MC4R for autonomic arousal circuits, MC3R for reward processing) may explain why PT-141 effects feel qualitatively different from PDE5 inhibitor effects in both animal models and human reports.

The hypothalamic site of action also explains the blood pressure side effect. MC4R activation in cardiovascular regulatory centers produces the mild, transient hypertension observed in clinical trials (mean +1.9 mmHg systolic). This is a direct consequence of CNS melanocortin signaling, not a peripheral vascular effect [10] PMID: 14963471 .

Critically, PT-141's mechanism is stimulus-dependent rather than continuous. It enhances the brain's response to sexual cues rather than producing arousal autonomously. This explains the clinical finding that efficacy requires the context of sexual stimulation — the drug primes neural circuits, but those circuits still need input to activate.

• MC4R agonism in hypothalamic circuits — stimulates oxytocin neuron firing in paraventricular nucleus, mediating central sexual arousal pathways
  PMID 17584134PMID 12851303
• MC3R agonism contributing to dopamine release in mesolimbic reward circuitry (nucleus accumbens, medial preoptic area, ventral tegmental area)
  PMID 17584134PMID 33455598
• Central nervous system mechanism distinct from peripheral vasodilation — acts on brain sexual motivation centers rather than genital blood flow
  PMID 12851303PMID 17584134
• Non-selective melanocortin receptor binding (MC1R–MC5R except MC2R) with nanomolar affinity — Ki ≈ 2.7 nM for MC4R, ≈ 4.1 nM for MC3R
  PMID 17584134

IV. Research Findings

The most robust clinical evidence supports sexual desire enhancement in premenopausal women with HSDD. The RECONNECT Phase 3 program — two identical randomized, double-blind, placebo-controlled trials enrolling 1,267 women — demonstrated statistically significant improvements on both coprimary endpoints: the Female Sexual Function Index–desire domain (FSFI-D) and the Female Sexual Distress Scale (FSDS-DAO item 13) [11] PMID: 33455598 .

Effect sizes were clinically meaningful: +0.35 change in desire scores vs. placebo (p<0.001) and −0.33 change in distress scores vs. placebo (p<0.001). Approximately 58% of bremelanotide-treated women reported meaningful improvement on the General Assessment Questionnaire, compared to 35% on placebo. Post hoc analysis found that the percentage of satisfying sexual encounters increased more than two-fold compared to placebo.

Long-term data from the 52-week open-label extension of RECONNECT (total exposure up to 76 weeks) confirmed sustained efficacy without new safety signals. Women continuing bremelanotide maintained improvements in desire (FSFI-D change +1.25 to +1.30 from baseline) and distress (FSDS-DAO change −1.4 to −1.7) that exceeded minimally clinically important differences [12] PMID: 33455598 .

For male erectile dysfunction, evidence is Phase 2 but mechanistically compelling. Intranasal PT-141 at doses above 7 mg produced statistically significant erectile responses in both healthy males and sildenafil-responsive ED patients, with onset of first erection in approximately 30 minutes [13] PMID: 14963471 . The mechanism — central MC4R-mediated oxytocin Oxytocin cyclic nonapeptide neuropeptide Neuropeptide studied for social bonding, wound healing & pain modulation release — offers a fundamentally different pathway from PDE5 inhibitors, making PT-141 a candidate for combination therapy or for patients who do not respond to existing treatments.

In women with sexual arousal disorder, a double-blind crossover study showed that a single 20 mg intranasal dose increased subjective feelings of genital arousal compared to placebo, though the physiological measure (vaginal pulse amplitude) did not reach statistical significance [14] PMID: 16839319 .

It is important to note that while FDA approval exists for HSDD in premenopausal women, all other applications remain investigational. Effect sizes, while statistically significant, are modest — a reality common to centrally-acting sexual dysfunction therapies.

• sexual-desire-enhancement phase_3_clinical
  PMID 33455598
• female-sexual-arousal phase_2_clinical
  PMID 16839319
• erectile-function phase_2_clinical
  PMID 14963471PMID 12851303
• sexual-distress-reduction phase_3_clinical
  PMID 33455598

V. Dosage Context Explained

The FDA-approved subcutaneous dose is 1.75 mg, self-administered in the abdomen or thigh at least 45 minutes before anticipated sexual activity. Maximum dosing is one injection per 24 hours and no more than eight doses per month. If no improvement in desire or distress is observed after 8 weeks of use, treatment should be discontinued [15] PMID: 33455598 .

Earlier clinical formulations used intranasal delivery at higher doses (7–20 mg). The nasal route was evaluated in Phase I and II trials for both male ED and female sexual dysfunction, but the subcutaneous formulation was selected for Phase 3 development due to more predictable pharmacokinetics and the ability to avoid the blood pressure spikes observed with intranasal absorption at higher doses [16] PMID: 14963471 .

Pharmacokinetic parameters for the approved subcutaneous route: - Bioavailability: ~100% - Tmax: 0.5–1.0 hours - Half-life: 2.5–2.7 hours - Protein binding: 21% - Elimination: 64.8% renal, 22.8% fecal

Blood pressure monitoring is recommended in patients with controlled hypertension. Mean increases of 1.9 mmHg systolic and 1.7 mmHg diastolic peak within 0–2 hours and resolve within 8–10 hours, with accompanying decreases in heart rate. No cumulative cardiovascular effects were observed in the 76-week exposure data.

Bremelanotide reduces gastric emptying, which can decrease the absorption of concomitantly administered oral medications. Co-administration with indomethacin or naltrexone should be avoided [17] PMID: 33455598 .

• Administration Routes

  subcutaneous

  Range

  1.75 mg as needed, ≥45 minutes before anticipated sexual activity

  FDA-approved dosing for premenopausal women with HSDD; max 1 dose per 24 hours, ≤8 doses per month

  PMID 33455598
• Administration Routes

  intranasal

  Range

  20 mg single dose (earlier clinical trials)

  premenopausal women with sexual arousal disorder; nasal formulation discontinued due to blood pressure concerns at higher doses

  PMID 16839319
• Administration Routes

  intranasal (male ED studies)

  Range

  7–20 mg

  Phase II trials in healthy males and mild-to-moderate ED patients; dose-dependent erectile responses observed above 7 mg

  PMID 14963471

VI. Side Effects: Research Context

Nausea is the dominant adverse event, affecting approximately 40% of bremelanotide-treated patients in the RECONNECT Phase 3 trials — compared to 1.3% on placebo. The nausea is typically transient (median onset 30 minutes, median duration 2.4 hours), mild to moderate in severity, and decreases in incidence with subsequent doses. Approximately 8% of patients discontinued treatment due to nausea [18] PMID: 33455598 .

Flushing (20.3%) and headache (11.3%) are the next most common adverse events, both substantially elevated over placebo rates. These effects are consistent with melanocortin receptor activation in central and peripheral tissues.

Cardiovascular effects are mild but mechanistically informative. The mean blood pressure increase (+1.9/1.7 mmHg systolic/diastolic) reflects MC4R-mediated activation of cardiovascular regulatory circuits in the hypothalamus. This elevation peaks within 0–2 hours and resolves within 8–10 hours, accompanied by reflexive decreases in heart rate. No cumulative effects were observed over 76 weeks of exposure. However, bremelanotide is contraindicated in uncontrolled hypertension and cardiovascular disease [19] PMID: 33455598 .

A case of acute hepatitis of unknown etiology was reported during the open-label extension. An independent hepatologist panel rated it as "unlikely due to bremelanotide" but could not exclude a drug contribution. This remains a single case without a clear mechanism.

Hyperpigmentation — darkening of skin at injection sites, gums, and face — has been reported with chronic use exceeding the recommended dosing frequency. This is an expected melanocortin effect (MC1R activation) and resolves with dose reduction or discontinuation.

No significant effects on clinical laboratory values, ECG parameters, body weight, depression scales, or suicidal ideation were observed in the clinical program.

• nausea (most common — ~40% of treated patients, typically transient, median duration 2.4 hours)
• flushing (~20%)
• headache (~12%)
• transient blood pressure elevation (mean +1.9 mmHg systolic, +1.7 mmHg diastolic, peaks within 0–2 hours, resolves within 8–10 hours)
• injection site reactions (~5%)
• vomiting (uncommon)
• hyperpigmentation at injection sites and gums reported with chronic use exceeding recommended frequency

VII. Frequently Asked Questions